Claudia Bartels1, Michael Wagner1, Steffen Wolfsgruber1, Hannelore Ehrenreich1, Anja Schneider1. 1. From the Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany; the Department of Psychiatry and Psychotherapy and the Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany; the German Center for Neurodegenerative Diseases, Bonn; and the Max Planck Institute of Experimental Medicine, Göttingen.
Abstract
OBJECTIVE: Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia. METHOD: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. RESULTS: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. CONCLUSIONS: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.
OBJECTIVE:Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia. METHOD: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. RESULTS: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. CONCLUSIONS: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.
Entities:
Keywords:
Dementia-Alzheimer-s Disease; Dementia-Other; Diagnosis And Classification; Geriatric Psychiatry; Psychotherapy
Authors: Aristotle N Voineskos; Benoit H Mulsant; Erin W Dickie; Nicholas H Neufeld; Anthony J Rothschild; Ellen M Whyte; Barnett S Meyers; George S Alexopoulos; Matthew J Hoptman; Jason P Lerch; Alastair J Flint Journal: JAMA Psychiatry Date: 2020-07-01 Impact factor: 21.596
Authors: Mitzi M Gonzales; Jasmeet Samra; Adrienne O'Donnell; R Scott Mackin; Joel Salinas; Mini E Jacob; Claudia L Satizabal; Hugo J Aparicio; Emma G Thibault; Justin S Sanchez; Rebecca Finney; Zoe B Rubinstein; Danielle V Mayblyum; Ron J Killiany; Charlie S Decarli; Keith A Johnson; Alexa S Beiser; Sudha Seshadri Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472